LEXX

Lexaria Bioscience Corp

0.5601

Jul 02 • 04:00PM ET -0.0119 (-2.08%)

Healthcare Biotechnology Canada Nano NASD

Peers: CMMB COCP CVKD HCWB HIND INAB MTVA NCEL OSRH XCUR

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	13.88M
Enterprise Value	8.31M
Income	-9.53M
Sales	0.37M
Book/sh	0.27
Cash/sh	0.21
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	7
IPO	Oct 10, 2006

P/E	-
Forward P/E	-
PEG	-
P/S	37.53
P/B	2.11
P/C	2.63
P/FCF	-
EV/EBITDA	-
EV/Sales	22.47
Quick Ratio	26.88
Current Ratio	26.88
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-0.48
EPS next Y	-0.31
EPS next Q	-0.06
EPS this Y	60.61%
EPS next Y	-19.23%
EPS next 5Y	24.86%
EPS past 3/5Y	18.80% 14.15%
Sales past 3/5Y	40.34% 17.53%
EPS Y/Y TTM	18.00%
Sales Y/Y TTM	-30.03%
EPS Q/Q	61.72%
Sales Q/Q	-88.51%
Earnings	Apr 14
EPS/Sales Surpr.	0.00% -

Insider Own	2.96%
Insider Trans	0.00%
Inst Own	6.01%
Inst Trans	-1.60%
ROA	-125.68%
ROE	-138.64%
ROIC	-142.99%
Gross Margin	76.20%
Oper. Margin	-2513.78%
Profit Margin	-2589.65%
SMA20	-5.71%
SMA50	-13.07%
SMA200	-31.90%
Trades

Shs Outstand	24.89M
Shs Float	24.05M
Short Float	1.50%
Short Ratio	2.48
Short Interest	0.36M
52W High	1.55 -63.86%
52W Low	0.46 21.76%
Volatility	5.81% 7.64%
ATR (14)	0.05
RSI (14)	42.86
Beta	0.34
Rel Volume	0.34
Avg Volume	145.15K
Volume	48,761

Perf Week	2.39%
Perf Month	-6.81%
Perf Quarter	-35.33%
Perf Half Y	3.00%
Perf YTD	-9.22%
Perf Year	-34.51%
Perf 3Y	-23.31%
Perf 5Y	-91.85%
Perf 10Y	-76.95%
Recom	1.00
Target Price	6.00
Prev Close	0.57
Price	0.56
Change	-2.08%

Jun-25-26 09:10AM	Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule (ACCESSWIRE)
Jun-23-26 09:25AM	Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule (ACCESSWIRE)
Jun-17-26 09:25AM	GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand (ACCESSWIRE)
Jun-09-26 09:25AM	Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway (ACCESSWIRE)
Jun-03-26 09:25AM	Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program (ACCESSWIRE)
09:15AM	Loading…
May-19-26 09:15AM	Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7 (ACCESSWIRE)
May-07-26 09:25AM	Lexaria Bioscience Releases Second Episode of Investor Video Series (ACCESSWIRE)
May-05-26 09:10AM	Lexaria Updates Progress on Human Study #7 (ACCESSWIRE)
May-01-26 09:25AM	Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications (ACCESSWIRE) +7.94%
Apr-29-26 09:10AM	Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended (ACCESSWIRE) -21.93%
Apr-23-26 09:05AM	Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs (ACCESSWIRE)
Apr-21-26 09:10AM	Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales (ACCESSWIRE)
Apr-15-26 09:10AM	Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property (ACCESSWIRE)
Apr-07-26 09:10AM	Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval (ACCESSWIRE) -6.60%
Apr-01-26 09:20AM	Lexaria to Begin New Human Clinical Study in GLP-1 (ACCESSWIRE) +11.04%
09:20AM	Loading…
Mar-26-26 09:20AM	Lexaria's Robust Patent Portfolio Continues to Grow (ACCESSWIRE)
Mar-24-26 09:15AM	Lexaria's Oral GLP-1 Drug Strategy Validated by Industry (ACCESSWIRE) +7.12%
Mar-04-26 09:25AM	Lexaria Announces New R&D Plans for 2026 (ACCESSWIRE) +5.04%
Feb-05-26 09:15AM	Lexaria Announces Positive Final Results From Human Pilot Study #5 (ACCESSWIRE) -8.66%
Jan-22-26 09:20AM	Lexaria Awarded Six Additional Patents (ACCESSWIRE)
Jan-12-26 09:10AM	Lexaria Releases Annual Letter from the CEO (ACCESSWIRE)
Dec-31-25 09:25AM	Lexaria releases additional results from Phase 1b study GLP-1-H24-4 (TipRanks) +13.46%
Dec-30-25 09:20AM	Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 (ACCESSWIRE)
Dec-23-25 09:29AM	Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 (ACCESSWIRE) -8.01%
Dec-16-25 04:00PM	Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -5.62% -18.86%
Dec-15-25 08:00AM	Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -33.58%
Nov-12-25 09:10AM	Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended (ACCESSWIRE)
Oct-09-25 09:20AM	Lexaria Bioscience Corp. Provides Strategic Update (ACCESSWIRE)
Sep-29-25 04:30PM	Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -6.40%
Sep-26-25 08:00AM	Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -31.37%
11:20AM	Loading…
Sep-19-25 11:20AM	Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain (ACCESSWIRE)
Aug-27-25 09:20AM	Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference (ACCESSWIRE)
Aug-15-25 09:25AM	Lexaria Bioscience announces last patient, last visit in Phase 1b GLP-1 study (TipRanks)
Aug-14-25 09:20AM	Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone (ACCESSWIRE)
Aug-06-25 09:20AM	GLP-1 "Arms Race" Broadens to Include Dozens of Companies (ACCESSWIRE)
Jul-28-25 09:25AM	Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study (ACCESSWIRE) -8.49%
Jul-23-25 09:25AM	Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry (ACCESSWIRE) +6.19%
Jun-23-25 09:15AM	Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide (ACCESSWIRE)
Jun-12-25 09:15AM	Lexaria Bioscience announces completion of GLP-1-H25-5 study (TipRanks)
Jun-11-25 09:05AM	Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule (ACCESSWIRE)
Jun-05-25 09:20AM	Lexaria Attending BIO International Convention (ACCESSWIRE)
May-12-25 09:00AM	Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company (ACCESSWIRE)
Apr-28-25 04:15PM	Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock (ACCESSWIRE) -9.63%
Apr-25-25 08:00AM	Lexaria Announces $2 Million Registered Direct Offering of Common Stock (ACCESSWIRE) -20.12%
Apr-23-25 09:10AM	Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology (ACCESSWIRE) +8.90%
Apr-03-25 09:10AM	Lexaria Updates its Ongoing Human Study GLP-1-H24-4 (ACCESSWIRE) -8.38%
Mar-18-25 09:15AM	Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R) (ACCESSWIRE) -5.25%
Feb-27-25 08:00AM	The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience (ACCESSWIRE)
Feb-24-25 08:00AM	Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm (ACCESSWIRE) +5.52%
Feb-20-25 08:00AM	Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide (ACCESSWIRE) -10.06%
Feb-11-25 08:00AM	Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy (ACCESSWIRE) -5.29%
Feb-06-25 09:40AM	Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway (ACCESSWIRE)
Feb-05-25 09:10AM	Lexaria Updates its Ongoing Human Study GLP-1-H24-4 (ACCESSWIRE) +5.08%
Jan-30-25 09:15AM	Lexaria Releases Annual Letter from the CEO (ACCESSWIRE)
Jan-15-25 09:20AM	Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval (ACCESSWIRE)
Jan-14-25 09:10AM	Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R) (ACCESSWIRE) -6.31%
Dec-19-24 09:05AM	Lexaria's Registered GLP-1 Study #4 Begins Dosing (ACCESSWIRE)
Dec-18-24 09:25AM	Lexaria Forms New Scientific Advisory Board (ACCESSWIRE)
Dec-17-24 09:10AM	Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience (ACCESSWIRE)
Dec-10-24 09:43AM	Lexaria Bioscience engages CRO for human pilot study of DehydraTEHC-liraglutide (TipRanks)
Dec-09-24 09:10AM	Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5 (ACCESSWIRE)
Nov-30-24 11:00AM	BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, and Surge Battery Metals (Newsfile)
11:00AM	BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, & Surge Battery Metals (Newsfile)
Nov-26-24 09:20AM	Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs (ACCESSWIRE)
Nov-25-24 09:00AM	Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled (ACCESSWIRE)
Nov-20-24 09:05AM	ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study (ACCESSWIRE)
Nov-14-24 09:10AM	Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study (ACCESSWIRE) -6.19%
Nov-13-24 09:20AM	Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss (ACCESSWIRE)
Nov-07-24 09:15AM	Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments (ACCESSWIRE) +5.94%
Oct-24-24 09:10AM	Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE)
Oct-22-24 09:20AM	Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE)
Oct-16-24 04:00PM	Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE)
Oct-15-24 08:25AM	Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -6.21%
Oct-09-24 09:05AM	Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing (ACCESSWIRE)
Oct-08-24 09:20AM	Lexaria Updates Current GLP-1 Market (ACCESSWIRE)
Oct-01-24 09:25AM	Lexaria Appoints Michael Shankman as Chief Financial Officer (ACCESSWIRE)
Sep-27-24 09:20AM	Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3 (ACCESSWIRE)
Sep-05-24 10:00AM	Lexaria Releases Strategic Letter from the Outgoing CEO (ACCESSWIRE)
09:00AM	Lexaria Welcomes Industry Veteran as New CEO (ACCESSWIRE)
Sep-03-24 08:30AM	Lexaria Enters a Material Transfer Agreement for DehydraTECH Research (ACCESSWIRE) -6.65%
Aug-29-24 09:25AM	Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules (ACCESSWIRE) +10.62%
Aug-27-24 09:20AM	First Results from Lexaria's Second GLP-1 Human Pilot Study (ACCESSWIRE)
Aug-22-24 09:20AM	Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE) -7.90%
Aug-21-24 09:00AM	Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE)
Aug-19-24 09:05AM	Positive Results from Lexaria's Molecular Characterization Study (ACCESSWIRE)
Jul-17-24 10:30AM	Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study (ACCESSWIRE)
Jul-16-24 09:20AM	Lexaria Preparing For Strategic Growth (ACCESSWIRE)
Jul-12-24 05:52PM	LEXX Stock Earnings: Lexaria Bioscience Misses EPS, Misses Revenue for Q3 2024 (InvestorPlace)
Jul-09-24 09:10AM	Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study (ACCESSWIRE)
Jul-08-24 09:10AM	Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy (ACCESSWIRE) -5.49%
Jun-24-24 06:40AM	7 A-Rated Penny Stocks to Beat June Gloom (InvestorPlace)
Jun-18-24 09:00AM	Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study (ACCESSWIRE)
Jun-14-24 07:15AM	7 A-Rated Biotech Stocks Worth Betting on in June (InvestorPlace) -6.08%
Jun-05-24 09:00AM	Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study (ACCESSWIRE)
Jun-04-24 07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
May-30-24 06:45AM	7 A-Rated Penny Stocks Work Betting On in H2 2024 (InvestorPlace) +5.00%
May-23-24 09:05AM	Lexaria Awards Contract For Third GLP-1 Human Pilot Study (ACCESSWIRE)
May-21-24 09:20AM	Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy (ACCESSWIRE)
May-17-24 09:10AM	Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study (ACCESSWIRE)
May-08-24 09:10AM	Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study (ACCESSWIRE)

Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. It operates through the IP licensing segment which generates revenue from customers by licensing its proprietary DehydraTECH technology. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.

CEO & DirectorMr. Richard C. Christopher

Chairman of the Scientific Advisory BoardMr. John M. Docherty M.Sc.

Chief Financial OfficerMr. Michael Shankman CPA

Director of OperationsMs. Kristin Hamilton

Head of LegalMs. Vanessa Carle

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BUNKA CHRISTOPHER	Director	Jul 29 '25	Buy	0.92	15,600	14,375	270,012	Jul 30 05:12 PM
BUNKA CHRISTOPHER	Director	Jul 30 '25	Buy	0.91	11,900	10,866	281,912	Jul 30 05:12 PM
McKechnie William Edward	Director	Jul 29 '25	Buy	0.91	5,000	4,532	18,191	Jul 30 12:37 PM
DOCHERTY JOHN MARTIN	President & CSO	Jul 29 '25	Buy	0.93	5,376	4,989	5,376	Jul 30 11:34 AM
Carle Vanessa	Secretary	Jul 29 '25	Buy	0.91	750	682	750	Jul 30 11:23 AM
CHRISTOPHER RICHARD	Chief Executive Officer	Jul 29 '25	Buy	0.91	15,000	13,641	65,000	Jul 30 11:14 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

LEXX

Lexaria Bioscience Corp

Upgrade your Finviz experience